Reduction of IgE Antibody in Human Allergic Subjects



Status:Completed
Conditions:Allergy
Therapuetic Areas:Otolaryngology
Healthy:No
Age Range:18 - 65
Updated:8/23/2018
Start Date:January 2011
End Date:June 20, 2017

Use our guide to learn which trials are right for you!

The purpose of this study is to determine whether a neuropeptide, substance P, when injected
along with an allergen, such as ragweed, can reduce allergic reactivity.

Allergic Rhinitis (Hay fever) affects many children and adults and is a risk factor for
development of asthma. This study utilizes the neurotransmitter, substance P, a small
molecule which is present in nerve endings, the brain, skin, lungs and the gastrointestinal
tract. Subjects will receive substance P and a low dosage of an allergen, such as ragweed in
an attempt to reduce allergic reactivity.

Inclusion Criteria:

- positive immediate type skin test to ragweed or grass pollen or a third (standardized)
allergen if both ragweed and grass pollen allergen are not positive

- volunteers should be available for allergen injections and then cutaneous titrations
for approximately 1 year from the start of the enrollment period

Exclusion Criteria:

- volunteer is pregnant or lactating

- abnormal electrocardiogram for subjects over 50 years of age

- use of beta adrenergic antagonists or tricyclic antidepressants
We found this trial at
1
site
303 E Chicago Ave
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
?
mi
from
Chicago, IL
Click here to add this to my saved trials